Fresh off receiving a long-awaited FDA clearance for its FreeStyle Libre 3 system, Abbott has racked up yet another major win for the continuous glucose monitor. Clinical results presented at the ...

(RTTNews) - Abbott (ABT) said late-breaking clinical data showed the FreeStyle Libre 3 system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day ...

Credit: Abbott. The FreeStyle Libre 3 reader is a standalone, small handheld device that displays real-time glucose readings. The Food and Drug Administration (FDA) has cleared a standalone reader to ...

Abbott noted that the FreeStyle Libre 3 System features a 7.9% overall mean absolute relative difference. "The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has cleared a next-generation integrated ...

Abbott Laboratories ABT presented late-breaking clinical data that demonstrate the FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor. The results were presented at the ...

This is now a Class I recall, meaning that the use of these continuous glucose monitoring systems could cause serious health consequences or death. Anna Gragert Senior Editor, Health and Home Anna ...

The Food and Drug Administration issued an “early alert” concerning FreeStyle Libre 3 and FreeStyle Libre Plus sensors used by people who have diabetes. The agency said Abbott Diabetes Care has sent a ...

Abbott Laboratories Inc. announced U.S. FDA clearance for its next-generation Freestyle Libre 3 continuous glucose monitor (CGM) system for people aged 4 years and older with diabetes. Accuracy of the ...

Health care technology company Abbott has recalled certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitoring systems because the sensors are displaying incorrect glucose ...